The FDA approved a supplemental NDA for Acetadote, an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in adults and pediatric patients who weigh 5 kg or greater with acute ingestion or from repeated supratherapeutic ingestion, approving changes to the Dosage and Administration section of the label, according to prescribing information posted to the agency’s website.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CPIX:
- Cumberland Pharmaceuticals Reports Q3 2024 Earnings and Developments
- Cumberland receives FDA orphan, RPDD designation for Ifetroban
- Cumberland announces publication comparing Caldolor and ketorolac
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
